Across TCGA pan-cancer cohorts, SNORA33 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of SNORA33’s most consistent transcriptional readouts.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where SNORA33 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SNORA33 is over-expressed in tumor, although a few such as KICH and PAAD show the opposite, repressed pattern.
BLCA, STAD, and COAD are the cancer types where SNORA33 tumor–normal differential expression is most reproducible.
RNA tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SNORA33 RNA (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.